Synthesis and characterization of a deuterium labeled stercobilin: A potential biomarker for autism

Stercobilin is an end‐stage metabolite of hemoglobin, a component of red blood cells. It has been found that there is a significantly lower concentration of stercobilin in the urine of people diagnosed with autism spectrum disorders, suggesting potential use as a biomarker. In vitro, we have synthesized stercobilin from its precursor bilirubin through a reduction reaction proceeded by an oxidation reaction. In addition, we have isotopically labeled the stercobilin product with deuterium using this protocol. Nuclear magnetic resonance investigations show the products of the unlabeled stercobilin (Rxn 1) and the deuterated stercobilin (Rxn 2) both had a loss of signals in the 5.0‐ to 7.0‐ppm range indicating proper conversion to stercobilin. Changes in the multiplicity of the sp3 region of the proton nuclear magnetic resonance suggest proper deuterium incorporation. Mass spectrometry studies of Rxn 1 show a difference in fragmentation patterns than that of Rxn 2 proposing potential locations for deuterium incorporation. This isotopologue of stercobilin is stable (>6 mo), and further analysis permits investigation for its use as a biomarker and potential quantitative diagnostic probe for autism spectrum disorders. Stercobilin, an end‐ stage metabolite of hemoglobin, is found at lower concentrations in the urine of people diagnosed with autism spectrum disorders, suggesting its potential use as a biomarker. We have synthesized a stable deuterium labeled isotopologue of stercobilin and continue to investigate it as a potential biomarker and therefore a quantitative diagnostic probe for autism spectrum disorders.